{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:23:03Z","timestamp":1756570983121,"version":"3.37.1"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,2,15]]},"DOI":"10.2169\/internalmedicine.3357-23","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T22:11:53Z","timestamp":1721254313000},"page":"581-584","source":"Crossref","is-referenced-by-count":3,"title":["Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis"],"prefix":"10.2169","volume":"64","author":[{"given":"Kentaro","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Nephrology, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Kanzaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kurashiki Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Salmon JH, Cacoub P, Combe B, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open 1: e000034, 2015.","DOI":"10.1136\/rmdopen-2014-000034"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Rymarz A, Matyjek A, Su\u0142ek-Jak\u00f3bczyk M, Mosakowska M, Niemczyk S. Impaired kidney function associated with increased risk of side effects in patients with small vessel vasculitis treated with rituximab as an induction therapy. J Clin Med 10: 786, 2021.","DOI":"10.3390\/jcm10040786"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Malpica Castillo LE, Palmer S, Zhu A, Deal AM, Chen SL, Moll S. Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases. Am J Hematol 95: E117-E120, 2020.","DOI":"10.1002\/ajh.25751"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kronbichler A, Windpessl M, Pieringer H, Jayne DRW. Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev 16: 633-643, 2017.","DOI":"10.1016\/j.autrev.2017.04.007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 89: 308-318, 2010.","DOI":"10.1097\/MD.0b013e3181f2caef"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Pendergraft WF 3rd, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 9: 736-744, 2014.","DOI":"10.2215\/CJN.07340713"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Arai Y, Yamashita K, Mizugishi K, et al. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. Hematology 20: 196-202, 2015.","DOI":"10.1179\/1607845414Y.0000000188"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nitta E, Izutsu K, Sato T, et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 18: 364-369, 2007.","DOI":"10.1093\/annonc\/mdl393"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Li SC, Chen YC, Evens AM, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor Fc\u03b3RIIIa 158(V\/F) polymorphism. Am J Hematol 85: 810-812, 2010.","DOI":"10.1002\/ajh.21818"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin&apos;s lymphoma. Bone Marrow Transplant 33: 921-923, 2004.","DOI":"10.1038\/sj.bmt.1704467"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zonozi R, Wallace ZS, Laliberte K, et al. Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease. Arthritis Rheumatol 73: 347-354, 2021.","DOI":"10.1002\/art.41501"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Voog E, Morschhauser F, Solal-C\u00e9ligny P. Neutropenia in patients treated with rituximab. N Engl J Med 348: 2691-2694, 2003.","DOI":"10.1056\/NEJM200306263482620"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 92: e20-e23, 2007.","DOI":"10.3324\/haematol.11031"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rauniyar R, Rauniyar R, Agrawal A, Yadav S, Avula S. Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report. Clin Case Rep 10: e05299, 2022.","DOI":"10.1002\/ccr3.5299"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 54: 1643-1650, 2019.","DOI":"10.1038\/s41409-019-0487-3"},{"key":"16","unstructured":"16. Zhang X, Rao M, Xu G. An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia. Arch Med Sci 20: 494-505, 2024."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Dunleavy K, Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 1: 795-802, 2005.","DOI":"10.1182\/blood-2004-08-3198"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JCW. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54: 723-732, 2006.","DOI":"10.1002\/art.21650"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tesfa D, Gelius T, Sander B, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro) myelocyte stage of granulopoiesis. Med Oncol 16: 374-379, 2008.","DOI":"10.1007\/s12032-008-9049-z"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/4\/64_3357-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T03:31:00Z","timestamp":1739590260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/4\/64_3357-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3357-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"article-number":"3357-23"}}